Trial
NCT03316898
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Allergan
Collaborators
—
Condition
Alzheimer's Disease
Intervention
AGN-242071
Why stopped
Business decision to stop the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-02